Baxdrostat Phase 3 Study for Uncontrolled Hypertension Completes Primary Data…

The Phase 3 study (NCT06034743) investigating baxdrostat in participants with uncontrolled and resistant hypertension completed its primary data collection on 2025-05-21, according to ClinicalTrials.gov. This milestone signifies that the main data collection for the trial's primary endpoint has concluded.

Background

The study, titled "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension," focuses on individuals whose blood pressure remains high despite current treatment. Uncontrolled hypertension is defined as hypertension despite a stable regimen of two antihypertensive agents, one of which is a diuretic. Resistant hypertension refers to hypertension despite a stable regimen of three or more antihypertensive agents, including a diuretic.

Trial design

The study (NCT06034743) is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial. It enrolled a total of 796 participants aged 18 years or older. The trial investigated the efficacy and safety of baxdrostat in participants with uncontrolled hypertension or resistant hypertension. Participants were randomized to receive either 1 mg or 2 mg of baxdrostat, administered once daily orally, or a placebo. The primary objective was to evaluate the effect of baxdrostat on the reduction of systolic blood pressure.

What this means

The completion of primary data collection for this Phase 3 trial is an important step in the development of baxdrostat. It indicates that all necessary data for the primary outcome measure has been gathered. The next stages typically involve data analysis, interpretation of results, and, if positive, potential submission to regulatory authorities. Clinicians and researchers will await the public release of the trial's key results to understand the potential role of baxdrostat in managing uncontrolled and resistant hypertension.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06034743, titled "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension," was posted on 2025-05-21 on clinicaltrials.gov.